Mean Cost of Drug to Market Is $879M

Overview

A recent study estimates the mean cost of bringing a new drug to market in the U.S. at $879.3 million, factoring in failed candidates and capital costs. The analysis highlights significant variations in costs across therapeutic areas.

Background

Understanding the costs associated with drug development is crucial for informing healthcare policies. This study provides an analysis of the economic factors influencing drug development costs in the U.S.

Data Highlights

Key Findings

• The mean cost to bring a new drug to market is $879.3 million.
• The mean cash outlay for developing a new drug is $172.7 million.
• Costs vary significantly by therapeutic area, with anti-infective drugs costing $378.7 million and pain medications exceeding $1.7 billion.
• R&D spending for large pharmaceutical companies grew by 27.9% from 2008 to 2019, while sales increased by 10%.
• The overall pharmaceutical industry saw a 25.8% increase in R&D spending despite a 15.6% decline in sales.
• Further research is needed to align drug development with public health needs and improve success rates.

Clinical Implications

Understanding the cost structure of drug development can inform policies.

Conclusion

This study provides insights into the economic landscape of drug development.

Related Resources & Content

1. JAMA Network Open, 2023 -- Costs of Drug Development and Research and Development Intensity in the US, 2000-2018
2. JAMA Network Open, 2025 -- Use of Clinical Trial Characteristics to Estimate Costs of New Drug Development
3. conexiant — Tariff Threat: Drugs Could Cost U.S. $750M More
4. Pain Medicine — Lowering pain and inflammation drug costs: evaluating the impact of a cost plus drug company model
5. The ASCO — IOM Workshop Explores Growing Problems in Patient Access to Cancer Drugs
6. Blood Cancer Journal — Challenges and Potential Enhancements in Drug Importation Proposals
7. Tariff Threat: Drugs Could Cost U.S. $750M More
8. Lowering pain and inflammation drug costs: evaluating the impact of a cost plus drug company model
9. IOM Workshop Explores Growing Problems in Patient Access to Cancer Drugs
10. Costs of Drug Development and Research and Development Intensity in the US, 2000-2018 | Clinical Pharmacy and Pharmacology | JAMA Network Open | JAMA Network
11. ICH Harmonised Guideline for Good Clinical Practice E6(R3) - Step 4 Final
12. E6(R3) Good Clinical Practice (GCP) | Guidance Portal
13. M11 Clinical Electronic Structured Harmonised Protocol | FDA
14. Master Protocols for Drug and Biological Product Development | FDA
15. Dynamic clinical trial success rates for drugs in the 21st century | Nature Communications
16. Real-World Evidence | FDA